NEOGENOMICS INC Q4 FY2024 earnings call

• Chris Smith thanked teammates for their commitment, mentioned the company has grown revenue double-digits for nine consecutive quarters and turned around adjusted EBITDA from negative $48 million in 2022 to positive $40 million in 2024. He also announced his retirement and introduced incoming CEO Tony Zook.
• Warren Stone discussed the optimization of the commercial business, with the field organization executing the strategy, driving volume growth especially in NGS. He mentioned the multi-year exclusive strategic commercial collaboration with Adaptive for MRD monitoring and the increase in Net Promoter Score to 74 in 2024.
• Andrew Lukowiak talked about innovation, including launching Neo PanTracer liquid biopsy and an upgrade to the Neo Comprehensive NGS panel, accelerating investment in clinical studies, and developing a dedicated research program for MRD.
• Jeff Sherman discussed margin expansion initiatives, with over 240 basis points of gross margin improvement in the second half and full year of 2024. He also provided details on fourth quarter and full year financial results, including revenue growth, operating expenses, and cash flow.

In the fourth quarter, revenue was $172 million, growing double-digits for the ninth consecutive quarter. Clinical testing volumes increased 9% with a 5% increase in revenue per test. Adjusted gross margins improved to 48%, the highest in 20 quarters. NGS saw 24% growth in the quarter and 34% for the year, representing over 30% of total revenue. For the full year 2024, revenue was $661 million, up 12% versus prior year. Adjusted gross profit was $311 million with an adjusted gross margin of 47%, an improvement of 245 basis points. Adjusted EBITDA increased over 1,000% to positive $40 million.

• Long-range financial plan targets top line growth to 12% to 13% annually, with NGS expected to grow 25% annually, gross margins to expand 100-150 basis points annually, and adjusted EBITDA margins to grow 250-300 basis points annually.
• Full year 2025 guidance: revenues of $735 million to $745 million (11%-13% growth) and adjusted EBITDA of $55 million to $58 million (38%-45% improvement). First quarter revenues expected to be about 23% of full year revenue, with 8%-10% of adjusted EBITDA earned in Q1.

• Pharma business challenges due to lack of year-end budget flush in Q4 and limitations in selling new RaDaR contracts.
• RaDaR litigation with a jury trial scheduled for October 2025, which could impact the business.

Q: Andrew Brackman asked about levers for potential upside in 2025 and risks.

A: Chris Smith mentioned momentum in NGS, launch of liquid biopsy, Adaptive partnership, and progress in Heme, noting pharma business challenges and RaDaR litigation as risks.

Q: Andrew Brackman asked about in-licensing and partnerships after the Adaptive deal.

A: Kareem Saad said no change in criteria for deals, looking at strategic fit, financial parameters, and Andrew Lukowiak noted increased inbound interest from companies.

Q: Puneet Souda asked about AUP assumptions, PanTracer gross margin impact, and pharma growth.

A: Jeff Sherman said AUP mix similar to prior year, PanTracer is a high-value test accretive to gross margins, and pharma expected to have modest growth.

Q: Tycho Peterson's representative asked about RaDaR 1.1 timeline and competition.

A: Chris Smith and Warren Stone discussed RaDaR 1.1 clearing validation, competitive sensitivity, and next-gen strategy.

Q: Mason Carrico asked about revenue contribution from new products and biomarker legislation.

A: Warren Stone said 13 new products launched in last two years, biomarker legislation is a tailwind but slow to impact.